Financial Data and Key Metrics Changes - In Q2 2025, IDEXX's revenue came in toward the midpoint of guidance, with organic sales increasing by 1% year over year, while orders grew organically by 2% [27][28] - Adjusted gross margin declined by 10 basis points year over year, primarily due to dilution from the Mod acquisition and unfavorable mix [29] - Free cash flow increased by 25% year over year to $147 million, representing 94% conversion versus adjusted net income [30] Business Line Data and Key Metrics Changes - In the HST segment, organic orders increased by 2% and organic sales increased by 4%, supported by positive pricing and volume increases in pharmaceutical and defense businesses [31] - In the FMT segment, organic orders increased by 7%, but organic sales declined by 2%, with growth in downstream energy and agriculture offset by declines in chemicals and semiconductor [32] - In the FST segment, organic sales grew by 2%, but organic orders declined by 7%, attributed to choppy order patterns [34] Market Data and Key Metrics Changes - Demand remained healthy in food, pharma, space, and defense applications, while weaker areas included chemicals, automotive, and semiconductor lithography [11] - The company experienced dynamic daily demand levels influenced by trade policy announcements, leading to a modest order recovery in July [12] Company Strategy and Development Direction - IDEXX aims to extend growth potential through variable levels of integration to win in advantaged markets, focusing on cross-business collaboration and operational improvements [14][18] - The company is actively pursuing tuck-in acquisitions to scale and expand critical capabilities in advantaged markets, with a focus on maintaining a strong balance sheet and cash flow generation [38][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the quality of its businesses despite lowering back half financial projections due to slower decision-making and order patterns [13][41] - The company anticipates a stable baseline for orders moving forward, with a focus on leveraging operational capabilities to drive growth [50][51] Other Important Information - IDEXX updated its full-year organic sales growth guidance to approximately 1%, down from 1% to 3%, and adjusted adjusted EPS guidance to $7.85 to $7.95 [36] - The company expects to fully mitigate tariff-related inflation with price increases and additional sourcing and supply chain savings [37] Q&A Session All Questions and Answers Question: Can you talk about the delayed orders on the semiconductor side and your confidence in those projects coming through? - Management noted that while there was oscillation in order patterns, they saw order recovery in July and expressed confidence in the stability of the baseline moving forward [48][50] Question: How much of the guidance cut is attributed specifically to Mott? - The guidance cut is primarily attributed to the MSS group and Mott, with frozen decision-making impacting revenue and profitability flow-through [93] Question: What is the current state of the life sciences segment? - The life sciences segment is experiencing a slow recovery, growing low single digits, with some areas weaker but generally offset by stronger applications in pharma drug discovery [98]